SINGAPORE, Aug. 2, 2026 /PRNewswire/ — XTransfer, the world’s leading B2B cross-border trade payment platform, is proud to announce it has been named, for the first time, to CNBC’s 2026 list of the World’s Top Fintech Companies (Payments Segment). The inclusion not only recognises XTransfer‘s ongoing commitment to empowering SMEs with secure, efficient and accessible cross-border payment solutions, but also highlights its growing influence in the industry.

The annual ranking, produced in collaboration with Statista, the world-leading statistics portal and industry ranking provider, recognises the most innovative and high-impact fintech firms globally.

“This recognition reflects the dedication of our team and the trust our customers and partners place in us every day,” said Bill Deng, Founder and CEO of XTransfer. “Cross-border financial operations can be complex, especially for SMEs. We focus on solving the real operational challenges behind international payments, reducing friction, improving visibility, and strengthening risk controls, so businesses can concentrate on growth.”

XTransfer‘s inclusion underscores the company’s growing role in the global payments ecosystem and its long-term mission to make cross-border trade payments simpler, safer, and more accessible for SMEs worldwide. XTransfer will continue to invest in compliance and product innovation, while deepening collaboration with top-tier financial institutions to help more businesses trade globally with confidence.

CNBC’s World’s Top Fintech Companies list evaluates thousands of firms across seven key segments, including Payments and Enterprise Technology. Companies were assessed based on quantitative KPIs, growth metrics, and industry influence, with data sourced from public reports, company submissions, and independent research.

Based on the results of the study, XTransfer is honoured to be recognised on CNBC’s World’s Top Fintech Companies 2026 list. View list here.

About XTransfer

XTransfer, the world’s largest B2B cross-border trade payment platform with over US$60 billion TPV in 2025, according to CIC. Founded in 2017 as one of the first payment platforms worldwide dedicated to B2B cross-border trade, we serve the largest customer base of over 890,000 registered SMEs globally.

We connect top-tier financial institutions directly to SMEs, the backbone of global trade, giving businesses of every size access to the same secure, compliant and seamless payment infrastructure once reserved for multinationals. As of March 31, 2026, we provide payment services across more than 200 countries and regions through partnerships with financial institutions, including some of the most established international banks around the world.

CHANGSHA, China, Aug. 3, 2026 /PRNewswire/ — The currently airing season of “Singer 2026” on Hunan TV and Mango TV features the strongest international lineup in its history.

As a long-time staple of the “Singer” series, Jessie J makes her return this season as a chart-topping sensation. Performing “My Way” and “California,” she captivated audiences with her signature powerful vocals and smooth transitions between notes.

Following this, John Legend, hailed as the “Godfather of Soul Music,” made his debut performance on The Singer stage. As a musician with an EGOT Grand Slam record, he performed the classics “All of Me” and “Imagine.” His warm, rich vocals and heartfelt piano accompaniment moved both the live judges and tens of thousands of online viewers.

In addition to the long-established legends, this season features three emerging international singers. American artist Stanaj makes his debut as a featured artist with the original single “Romantic” —a vibrant track blending R&B and electronic elements that showcases authentic American pop vocals.

Malaysian artist Azora Chin, also a debut artist, combines refined narrative skill with exceptional vocal prowess, effortlessly navigating diverse musical styles—from the atmospheric ballad “March” to the powerfully charged “As a Monster,” with “Grandma’s Words” standing out as his most impactful and heartfelt work of the season.

Elliot James Reay, a British boy born in the 2000s, made his debut in China as a substitute singer. During the recent qualifying rounds, he advanced to the “King of Songs Sprint Month” stage thanks to the grand production and powerful sound pressure of “Skyfall.”

Focus on Hunan TV and Mango TV to witness the ultimate clash of global musical forces on the China stage.

In the news release, “Spider-Man: Brand New Day” Swings to a $19.2 Million IMAX Opening Weekend in China, Setting Franchise-Best Records, issued 03-Aug-2026 by IMAX over PR Newswire, we are advised by the company that the subheading, should read “IMAX’s Biggest Hollywood Opening Day in China Since 2019” rather than “IMAX’s Biggest Hollywood Opening Day and Weekend in China Since 2019” as originally issued inadvertently. The complete, corrected release follows:

“Spider-Man: Brand New Day” Swings to a $19.2 Million IMAX Opening Weekend in China, Setting Franchise-Best Records

IMAX’s Biggest Hollywood Opening Day in China Since 2019

BEIJING, Aug. 3, 2026 /PRNewswire/ — IMAX China Holding, Inc. (HKEX: 1970) today announced that Sony Pictures/Marvel’s “Spider-Man: Brand New Day” grossed more than $19.2 Million at the IMAX box office in China, delivering IMAX franchise records for both opening day and opening weekend. The record-setting debut marks IMAX’s biggest opening day for a Hollywood release in China since “Avengers: Endgame” in 2019, while also establishing a new opening weekend record for a single-character superhero film. IMAX accounted for 16% of the film’s nationwide opening weekend box office with roughly 1% of total screens, delivering the highest IMAX index ever for the live action franchise.

The momentum was evident from the start, with IMAX midnight screenings generating more than $1.2 Million, representing 30% of the film’s nationwide midnight grosses. The strong demand translated into a new 2026 IMAX China midnight-screening record, and achieved the biggest-ever IMAX midnight-screening performance for both the “Spider-Man” franchise and a single-character superhero film.

“Congratulations to our partners at Sony Pictures and Marvel Studios on this phenomenal opening,” said Daniel Manwaring, CEO of IMAX China. “This landmark performance once again demonstrates IMAX’s unique ability to elevate great storytelling into must-see theatrical events, while underscoring the Chinese market’s enduring appetite for event cinema. This powerful opening further fuels our momentum through the rest of the summer season, backed by a strong content pipeline ahead.”

As “Spider-Man: Brand New Day” continues its run across IMAX theatres nationwide, Christopher Nolan’s “The Odyssey”, the world’s first feature film shot entirely with IMAX film cameras, will open in IMAX theatres across China on August 14, following nationwide previews from August 8. The IMAX summer lineup also includes “Kung Fu Soccer” and “All Wishes Come True!”, currently playing in theatres, as well as the upcoming “The End of Oak Street”.

About IMAX China

IMAX China is a subsidiary of IMAX Corporation and was incorporated as a limited liability company under the laws of Cayman Islands. IMAX China was established by IMAX Corporation specifically to oversee the expansion of IMAX’s business throughout Greater China. Shares of IMAX China trade on the Hong Kong Stock Exchange under the stock code “1970”.

About IMAX Corporation

IMAX (NYSE: IMAX) is a global leader in entertainment technology, delivering immersive cinematic experiences through proprietary software, architecture, and projection systems. Filmmakers, studios, and artists worldwide use IMAX to connect with audiences at scale, making its network one of the most powerful platforms for blockbuster events and entertainment.

Headquartered in New York, Toronto, and Los Angeles, IMAX operates 1,865 systems across 91 countries and territories as of March 31, 2026. IMAX China Holding, Inc., a subsidiary of IMAX Corporation, trades on the Hong Kong Stock Exchange under stock code “1970.” IMAX and related marks are trademarks of IMAX Corporation. For more information, visit www.imax.com.

CHICAGO, Aug. 3, 2026 /PRNewswire/ — Cboe Global Markets, Inc. (Cboe: CBOE), a leading global markets operator and pioneer in equity and index derivatives, today announced it has completed the sale of Cboe Australia (now TMX Australia Exchange) to TMX Group Limited (TMX Group).

“Over the past year, Cboe has taken decisive steps to refocus our business, concentrate resources on our core strengths and invest in our most compelling growth opportunities. The sale of Cboe Australia is a part of that strategy, allowing us to further align our organization and capital with our long-term priorities,” said Prashant Bhatia, EVP, Head of Enterprise Strategy & Corporate Development at Cboe. “Looking ahead, Cboe remains committed to maintaining a strong presence in Asia Pacific – a strategically important region where demand for Cboe’s U.S. equities, derivatives, market data and educational offerings continues to accelerate.”

Cboe’s planned sale of Cboe Canada to TMX Group, announced in April alongside its planned sale of Cboe Australia, is expected to close at a later date, subject to local regulatory approvals and customary closing conditions.

About Cboe Global Markets

Cboe Global Markets (Cboe: CBOE) is a leading global markets operator with a long history of innovation in equity and index derivatives. Since launching the world’s first listed options exchange in 1973, Cboe has pioneered landmark products, including the introduction of S&P 500® index options and the creation of the VIX® Index, the world’s leading gauge of market volatility, reshaping how investors manage risk and access opportunity. Today, Cboe operates derivatives, equities, and FX markets, providing trading, clearing, and investment solutions for customers worldwide. To learn more, visit www.cboe.com.

CBOE-C
CBOE-OE

Cboe®, Cboe Global Markets®, and VIX ® are registered trademarks or service marks of Cboe Exchange, Inc and S&P 500® is a registered trademark of Standard & Poor’s Financial Services LLC. All other trademarks and service marks are the property of their respective owners. 

Cautionary Statements Regarding Forward-Looking Information

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. You can identify these statements by forward-looking words such as “may,” “might,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential” or “continue,” and the negative of these terms and other comparable terminology. All statements that reflect our expectations, assumptions or projections about the future other than statements of historical fact are forward-looking statements. These forward-looking statements, which are subject to known and unknown risks, uncertainties and assumptions about us, may include projections of our future financial performance based on our growth strategies and anticipated trends in our business. These statements are only predictions based on our current expectations and projections about future events. There are important factors that could cause our actual results, level of activity, performance or achievements to differ materially from those expressed or implied by the forward-looking statements.

We operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible to predict all risks and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

Some factors that could cause actual results to differ include: the loss of our right to exclusively list and trade certain index options and futures products; economic, political and market conditions; compliance with legal and regulatory obligations; price and new products and services competition and consolidation in our industry; decreases in trading or clearing volumes, market data fees or a shift in the mix of products traded on our exchanges; legislative or regulatory changes or changes in tax regimes; our ability to protect our systems and communication networks from security vulnerabilities and breaches; our ability to attract and retain skilled management and other personnel; increasing competition by foreign and domestic entities; our business and operational dependence on and exposure to risk from third parties; factors that impact the quality and integrity of our and other applicable indices; our ability to manage our global operations, growth, and strategic acquisitions, wind downs, divestitures, or alliances effectively; increases in the cost of the products and services we use; our ability to operate our business without violating the intellectual property rights of others and the costs associated with protecting our intellectual property rights; our ability to minimize the risks, including our credit, liquidity, market, investment, counterparty, and default risks, associated with operating our  clearinghouses; our ability to accommodate trading and clearing volume and transaction traffic, including significant increases, without failure or degradation of performance of our systems; misconduct by those who use our markets or our products or for whom we clear transactions; challenges to our use of open source software code; our ability to meet our compliance obligations, including managing our business interests and our regulatory responsibilities; the loss of key customers or a significant reduction in trading or clearing volumes by key customers; damage to our reputation; the ability of our compliance and risk management methods to effectively monitor and manage our risks; restrictions imposed by our debt obligations and our ability to make payments on or refinance our debt obligations; our ability to maintain an investment grade credit rating; impairment of our goodwill, long-lived assets, investments or intangible assets; the accuracy of our estimates and expectations; and litigation risks and other liabilities. More detailed information about factors that may affect our actual results to differ may be found in our filings with the SEC, including in our Annual Report on Form 10-K for the year ended December 31, 2025 and other filings made from time to time with the SEC.

We do not undertake, and we expressly disclaim, any duty to update any forward-looking statement whether as a result of new information, future events or otherwise, except as required by law. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.

• Minjuvi^® (tafasitamab), in combination with rituximab and lenalidomide, is the first and only chemotherapy-free CD19 and CD20 dual-targeted immunotherapy combination regimen listed on the Pharmaceutical Benefits Scheme (PBS) for adults with relapsed or refractory follicular lymphoma (R/R FL) (Grade 1-3a).^[1],[2]
• In the pivotal Phase 3 inMIND clinical trial, patients with R/R FL receiving the Minjuvi combination regimen experienced a significant improvement in progression-free survival, with a 57% reduction in the risk of disease progression, relapse or death, compared with placebo plus lenalidomide and rituximab.^[3]
• Follicular lymphoma is the second most common non-Hodgkin lymphoma (NHL), with over 10,000 Australians living with the disease and approximately 1,500 Australians diagnosed each year.^[4],[5]

SINGAPORE, Aug. 2, 2026 /PRNewswire/ — Independent biopharmaceutical company Specialised Therapeutics (ST) is pleased to announce the listing of Minjuvi^® (tafasitamab), in combination with rituximab and lenalidomide, on the Pharmaceutical Benefits Scheme (PBS) for the treatment of Australian adults with relapsed or refractory follicular lymphoma (R/R FL) (Grade 1-3a).^[1] This milestone follows the Australian registration of Minjuvi for R/R FL by the Therapeutic Goods Administration (TGA) in April 2026, via the Project Orbis process.^[6]

The PBS listing of Minjuvi marks the availability of the first and only chemotherapy-free CD19 and CD20 dual-targeted immunotherapy combination regimen funded in Australia for this group of patients.^[1],[2] Effective 1 August 2026, eligible patients with FL who have experienced relapses or disease progression on existing therapies will now have equitable access to a new treatment option for this difficult-to-treat condition.^[1]

“As the first new therapy to be reimbursed on the PBS for R/R FL in nine years, we are extremely proud to have partnered with Incyte to bring Minjuvi to Australia,” said Carlo Montagner, ST Chief Executive Officer. “After securing TGA registration for Minjuvi in R/R FL earlier this year, we have been focused on expediting PBS listing to ensure eligible Australian patients could have subsidised access to a new treatment option that may help lower the risk of disease progression, relapse or death, without delay.”

ST entered into an exclusive distribution agreement with Incyte (NASDAQ:INCY) in 2021 to commercialise Minjuvi in Australia, New Zealand and Singapore.

Minjuvi is a CD19 targeting immunotherapy that works within a patient’s immune system to help find and eliminate malignant B-cells.^[7] In combination with rituximab and lenalidomide, Minjuvi delivers a complementary immune-mediated approach that helps control disease progression and supports improved long-term outcomes for patients with follicular lymphoma.^[7]

The PBS reimbursement underscores the growing recognition of innovative immunotherapy-based treatment strategies in follicular lymphoma and reinforces ST’s commitment to improving access to life-changing therapies for patients across the Asia-Pacific region.

“While follicular lymphoma can be a slow-growing disease that usually responds well to the first treatment, most patients are not cured. Many patients experience frequent relapses and require multiple therapies over their lifetime, which become progressively less effective, especially for those whose disease comes back soon after initial chemotherapy treatment,” said Associate Professor Philip Thompson, Clinical Haematologist at the Peter MacCallum Cancer Centre and Royal Melbourne Hospital in Melbourne. “Today’s PBS listing announcement is welcome news for the Australian clinical and patient community, providing us with a new, chemotherapy-free immunotherapy treatment for R/R FL.”

Minjuvi is administered via intravenous (IV) infusion in a clinic or hospital setting.^[7] Patients with R/R FL receive up to 12 treatment cycles of Minjuvi, along with oral lenalidomide capsules, while rituximab is delivered intravenously for the first five cycles.^[7]

“Knowing that a chemotherapy-free immunotherapy is now funded by the PBS is an important development for the follicular lymphoma community,” said Sharon Winton, Chief Executive Officer of Lymphoma Australia. “As patients manage the challenges of recurring disease, this new treatment milestone offers a valuable option that is deeply meaningful to them and their families.”

The PBS listing of Minjuvi for R/R FL means these patients will now have equitable access to a new targeted immunotherapy combination treatment when they need it. It is important that patients with R/R FL speak with their doctor to understand the most suitable treatment option available for them.

For further details on Minjuvi, contact your healthcare professional and please refer to the approved Australian Consumer Medicine Information or Product Information available from the TGA website.

PBS Information:

This medicine is listed on the Pharmaceutical Benefits Scheme (PBS) — AUTHORITY REQUIRED. Refer to the PBS Schedule www.pbs.gov.au for full authority information.

Important Safety Information on Minjuvi^[7]

Minjuvi should be administered to patients with an active infection only if the infection is treated appropriately and well controlled. Patients with a history of recurring or chronic infections may be at increased risk of infection and should be monitored appropriately. Patients should be advised to contact their healthcare professionals if fever or other evidence of potential infection, such as chills, cough or pain on urination, develops.

Treatment with Minjuvi in combination with lenalidomide and/or rituximab should not be initiated in female patients unless pregnancy has been excluded. In the inMIND study, the most common adverse reactions were infections (68%), including viral infections (41%) and bacterial infections (27%); neutropenia (57%), rash (36.4%), asthenia (34.9%), pyrexia (19%), thrombocytopenia (17%), anaemia (17%), infusion related reaction (15.9%), pruritus (15.6%), and headache (10.4%). The most common serious adverse reactions were infections (26%), including viral infections (13%) and bacterial infections (6%), febrile neutropenia (2.8%), and pyrexia (1.8%).

Treatment with tafasitamab can cause serious or severe myelosuppression including neutropenia, thrombocytopenia, and anaemia. Complete blood counts should be monitored throughout treatment and prior to administration of each treatment cycle.

Ends.

About Minjuvi^® (tafasitamab)

Minjuvi^® (tafasitamab) is a humanised Fc-modified cytolytic CD19-targeting monoclonal antibody. Minjuvi incorporates an XmAb^® engineered Fc domain, which mediates B-cell lysis through apoptosis and immune effector mechanism including Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Antibody-Dependent Cellular Phagocytosis (ADCP).^[7] Incyte licenses exclusive worldwide rights to develop and commercialise Minjuvi from Xencor, Inc. 

In the U.S., Monjuvi^® (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL). Additionally, Monjuvi received accelerated approval in the United States in combination with lenalidomide for the treatment of adult patients with relapsed or refractory DLBCL not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for ASCT. 

Monjuvi is not indicated and is not recommended for the treatment of patients with relapsed or refractory marginal zone lymphoma outside of controlled clinical trials. 

In Europe, Minjuvi^® (tafasitamab) received conditional Marketing Authorisation from the European Medicines Agency in combination with lenalidomide, followed by Minjuvi monotherapy, for the treatment of adult patients with relapsed or refractory DLBCL who are not eligible for ASCT. In addition, in December 2025, the EMA approved Minjuvi, in combination with lenalidomide and rituximab, for the treatment of adult patients with relapsed or refractory FL (Grade 1-3a) after at least one line of systemic therapy. 

In Japan, Minjuvi is approved in combination with lenalidomide for the treatment of adults with relapsed or refractory DLBCL. Minjuvi is also approved in combination with rituximab and lenalidomide for adult patients with relapsed or refractory FL (2L+ FL). 

In Australia, Minjuvi^® (tafasitamab) is indicated in combination with lenalidomide followed by Minjuvi monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT).^[7]

▼ This medicine is included in the TGA Black Triangle Scheme. Please report suspected adverse events to the TGA.^[7]

XmAb^® is a registered trademark of Xencor, Inc. 

Monjuvi and Minjuvi are registered trademarks of Incyte. 

About the inMIND Study^[3]

A global, double-blind, randomised, placebo-controlled Phase 3 study, inMIND (NCT04680052) evaluated the efficacy and safety of Minjuvi (tafasitamab) in combination with rituximab and lenalidomide compared with placebo in combination with rituximab and lenalidomide in patients with relapsed or refractory follicular lymphoma (FL) Grade 1 to 3a or relapsed or refractory nodal, splenic or extranodal marginal zone lymphoma (MZL). The study enrolled a total of 654 adults (age ≥18 years), including 548 participants with R/R FL. 54 Australians participated in the study across 12 local trial sites around the country.

The primary endpoint of the study is progression-free survival (PFS) by investigator assessment in the FL population, and the key secondary endpoints are PFS in the overall population as well as positron emission tomography complete response (PET-CR) and overall survival (OS) in the FL population.

The clinical trial met its primary endpoint, with the data demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS) in comparison to placebo added to lenalidomide and rituximab. Patients receiving Minjuvi in combination with rituximab and lenalidomide achieved a median PFS by investigator assessment of 22.4 months (95% CI, 19.2-not evaluable [NE]) compared to 13.9 months (95% CI, 11.5-16.4) in the control arm (hazard ratio [HR]: 0.43 [95% CI, 0.32-0.58]; P<0.0001). The PFS assessed by an Independent Review Committee (IRC) was consistent with investigator-based results. Median PFS by IRC was not reached (95% CI, 19.3-NE) in the Minjuvi group versus 16.0 months (95% CI, 13.9-21.1) in the placebo group (HR: 0.41 [95% CI, 0.29-0.56].

Minjuvi was generally well-tolerated, with a manageable safety profile. Safety and tolerability were comparable with the addition of Minjuvi to lenalidomide in combination with rituximab. The most common adverse reactions in the Phase 3 study (≥20%) in patients receiving Minjuvi, excluding laboratory abnormalities, were respiratory tract infections (including COVID-19 infection and pneumonia), diarrhoea, rash, fatigue, constipation, musculoskeletal pain and cough.

About Specialised Therapeutics

Founded in 2007, Specialised Therapeutics is an independent specialty pharmaceutical company, providing novel therapies and technologies to patients in Australia, New Zealand and across Southeast Asia. Headquartered in Singapore, ST partners with global pharmaceutical, biotech and diagnostic companies to bring novel healthcare opportunities to patients who are impacted by a range of diseases. ST has built a strong track record of success, navigating complex regulatory, reimbursement and commercialisation environments in its diverse regions across multiple therapeutic areas. The ST mission is to provide specialty therapies where there is an unmet need to communities that would otherwise not have ready access to such therapies. The company’s broad therapeutic portfolio currently includes novel agents in oncology, haematology, CNS, neurology, endocrinology, ophthalmology and supportive care, although it is not confined to these areas.           

Additional information can be found at www.stbiopharma.com.

REFERENCES:

SINGAPORE, Aug. 2, 2026 /PRNewswire/ — Artificial intelligence has transformed academic writing. Today, researchers can summarize hundreds of papers, generate literature reviews, and even draft complete manuscripts in minutes. But as AI becomes an indispensable research tool, a new challenge is emerging: many AI-generated citations cannot be trusted.

Fabricated references, incorrect author names, invalid DOIs, and nonexistent journal articles have become one of the most widely recognized limitations of large language models. While AI dramatically improves writing efficiency, unreliable citations threaten the credibility of research itself.

Wispaper, an AI-powered academic research platform, believes the next generation of academic AI must solve this trust problem—not simply produce more text.

Today, the company announced its next-generation AI Research Agent, together with True Cite, a citation verification system designed to help researchers build papers on authentic, verifiable academic sources instead of AI-generated references.

Unlike conventional AI writing assistants that focus on content generation, Wispaper is built around the complete research process. The platform helps researchers discover research gaps, explore hypotheses, organize literature, and develop stronger scientific arguments before writing begins. Throughout this workflow, True Cite enables users to verify references against real academic publications, helping reduce the risk of citation hallucinations while improving research reliability.

“Everyone is talking about how fast AI can write,” said a Wispaper spokesperson. “We believe the more important question is whether researchers can trust what AI produces. Scientific progress depends on evidence, and evidence begins with trustworthy sources.”

As AI adoption accelerates across universities and research institutions, expectations for academic AI are evolving. Researchers are no longer looking only for writing assistants—they need AI systems that support scientific reasoning while maintaining academic integrity.

By combining reasoning-first research workflows with citation verification, Wispaper aims to redefine the role of AI in academia—from a text generator to a trusted research partner.

About WisPaper

WisPaper is an AI-powered academic research agent designed as a full-stack research accelerator. It supports literature retrieval, analysis, experiment design, execution, and paper writing within a unified workflow, helping researchers manage complex scientific tasks more efficiently across disciplines. For more information, visit https://wispaper.ai/?utm_source=news.